Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Neurology

Managing BPAN: Therapies and Treatments

At a Glance

BPAN has no cure that stops the disease, so treatment is supportive and individualized. Neurologists and therapists manage seizures, movement symptoms, communication, swallowing, sleep, behavior, and comfort; iron chelation is not standard care because benefit is unproven and harm is possible.

Managing Beta-propeller Protein-Associated Neurodegeneration (BPAN) is a marathon, not a sprint. Because there is currently no cure or treatment that stops the underlying disease, medical care focuses on “supportive therapy.” This means your medical team works to manage symptoms, improve quality of life, and help maintain activity and comfort as much as possible [1][2].

A Team-Based Approach to Care

Because BPAN affects many parts of the body, care is most effective when it involves a multidisciplinary team. This team typically includes neurologists, geneticists, and several types of therapists who reassess needs over time [1].

  • Physical Therapy (PT): Focuses on maintaining mobility, preventing muscle tightness (contractures), and selecting adaptive equipment like walkers or specialized seating [3][4].
  • Occupational Therapy (OT): Helps with “activities of daily living,” such as eating, dressing, and using technology [5].
  • Speech and Language Therapy: This is a high priority in BPAN. Since individuals often understand more than they can say, therapists focus on Augmentative and Alternative Communication (AAC), such as picture boards or speech-generating devices, to aid expression [5][4].
  • Feeding and Nutrition: As swallowing difficulties can emerge, specialists monitor the ability to eat safely and ensure proper nutrition [6].

Managing Seizures

Seizures are a major part of the first phase of BPAN. There is no “single best” antiseizure medication for BPAN; instead, doctors choose treatments based on the specific type of seizures, age, and individual safety factors [7][8].

  • Individualized Treatment: Medications like valproic acid or levetiracetam are general examples of antiseizure drugs, but doctors tailor the choice. For instance, valproic acid carries important liver and pregnancy-related risks, while levetiracetam can sometimes worsen behavioral irritability [9]. Never stop or change medications abruptly without guidance from your neurologist.
  • Trends Over Time: Many families find that seizure control becomes easier during adolescence, and some even become seizure-free [10][11]. However, it is vital to keep a “rescue medication” plan in place for sudden or prolonged seizures [12].
  • Infantile Spasms: If a child develops infantile spasms, this is a medical emergency that requires urgent specialist treatment (sometimes involving therapies like ACTH or corticosteroids) [9][13].

Movement Symptoms: Levodopa and Botox

In the second phase of BPAN, new symptoms like parkinsonism (stiffness and tremors) and dystonia (involuntary twisting) may appear [1].

  • Levodopa: This medication is commonly used in Parkinson’s disease. In some isolated reports, a trial of levodopa helped with stiffness, sleep, or swallowing [6]. However, the response varies widely, and its long-term effectiveness in BPAN is not yet fully understood [14]. This should always be a monitored specialist trial, as levodopa can cause side effects like nausea, low blood pressure, sleep or behavioral changes, and dyskinesia.
  • Botulinum Toxin (Botox): Specialist-guided injections can sometimes relax severely stiff muscles. However, these carry risks such as weakening nearby muscles or temporarily worsening swallowing [15].

Why Iron Chelation is Not Standard Care

It might seem logical to use medications that remove iron (iron chelation) since BPAN involves iron buildup in the brain. However, clinical evidence suggests this may not be helpful and could even be harmful for BPAN patients [16].

  • Worsening Symptoms: In isolated case reports, medications like deferiprone (an iron chelator) have been linked to a worsening of parkinsonian symptoms [17].
  • No Clear Benefit: Other reports showed that even after a full year of chelation therapy, there was no improvement in movement, speech, or thinking [18].
  • The Underlying Cause: Because BPAN is primarily a “recycling” problem within the cell, simply removing iron does not fix the underlying disease [19]. For these reasons, iron chelation carries potentially serious toxicities and is not recommended as standard care outside of formal research studies [16][17].

Daily Symptom Management and Planning

A significant part of BPAN management involves practical, day-to-day supportive care:

  • Constipation and Pain: Proactive bowel regimens and routine pain assessments are essential, especially if communication is difficult.
  • Sleep and Behavior: Chronic sleep disturbances and behavioral outbursts may require behavioral or psychiatric support.
  • Adult Transition: Families should proactively work with a care coordinator to establish a plan for transitioning from pediatric to adult neurology services, addressing advanced care planning, and setting up supported decision-making frameworks.

Common questions in this guide

Does BPAN have a cure, or is treatment mainly supportive?
There is currently no cure or treatment known to stop the underlying disease in BPAN. Care focuses on supportive therapy that manages seizures and other symptoms, preserves mobility and communication, supports safe eating, and improves comfort and quality of life.
How are seizures treated in someone with BPAN?
There is no single best antiseizure medicine for BPAN. A neurologist chooses medication based on seizure type, age, and safety factors; valproic acid and levetiracetam are examples, and a rescue medicine plan may be needed for sudden or prolonged seizures. Infantile spasms need urgent specialist treatment.
Could levodopa or Botox improve BPAN stiffness or dystonia?
Levodopa helps some people with stiffness, sleep, or swallowing, but response in BPAN varies and long-term benefit is uncertain. A specialist should monitor a trial because side effects can include nausea, low blood pressure, sleep or behavior changes, and abnormal involuntary movements. Botulinum toxin injections may relax severely stiff muscles, but can weaken nearby muscles or temporarily worsen swallowing.
Why are iron-removing medicines not routinely recommended for BPAN?
Iron-chelating medicines such as deferiprone have not shown a clear benefit for BPAN and have been linked in some reports to worsening Parkinson-like movement symptoms. They can also cause serious toxicities, so iron chelation is not standard care outside formal research studies.
What therapies can help with communication, mobility, and daily activities in BPAN?
Physical therapy can help maintain mobility and prevent muscle tightness, while occupational therapy supports eating, dressing, and technology use. Speech and language therapy can introduce augmentative and alternative communication, such as picture boards or speech-generating devices, when speaking is difficult.
How are swallowing and nutrition problems monitored in BPAN?
Feeding and nutrition specialists monitor whether eating is safe and whether nutrition is adequate as swallowing problems develop. Families should ask the care team what signs of swallowing difficulty or silent aspiration to watch for and whether an evaluation is needed.
How can families prepare for the transition from pediatric to adult BPAN care?
Families can work with a care coordinator early to organize the move from pediatric to adult neurology services. Planning should also address ongoing therapies, advanced care planning, and supported decision-making.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Given that seizures can change over time, what is our long-term plan for monitoring or adjusting medications?
  2. 2.What are the specific risks and benefits of a levodopa or Botox trial for the current motor symptoms?
  3. 3.How can we ensure communication needs are being met if speaking is difficult?
  4. 4.What specific signs of swallowing difficulty or 'silent' aspiration should we be looking for at home?
  5. 5.Are there any clinical trials or research studies that we might be eligible for in the future?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (19)
  1. 1

    Consensus clinical management guideline for beta-propeller protein-associated neurodegeneration.

    Wilson JL, Gregory A, Kurian MA, et al.

    Developmental medicine and child neurology 2021; (63(12)):1402-1409 doi:10.1111/dmcn.14980.

    PMID: 34347296
  2. 2

    Generation of two human iPSC lines from fibroblasts of BPAN patients carrying pathogenic variants in the WDR45 gene.

    Gasparini G, Kraus C, Rusha E, et al.

    Stem cell research 2026; (90()):103892 doi:10.1016/j.scr.2025.103892.

    PMID: 41496281
  3. 3

    Ischemic Fasciitis of the Left Buttock in a 40-Year-Old Woman with Beta-Propeller Protein-Associated Neurodegeneration (BPAN).

    Sakamoto A, Arai R, Okamoto T, et al.

    The American journal of case reports 2018; (19()):1249-1252 doi:10.12659/AJCR.911300.

    PMID: 30341275
  4. 4

    Psychometric outcome measures in beta-propeller protein-associated neurodegeneration (BPAN).

    Gavazzi F, Pierce SR, Vithayathil J, et al.

    Molecular genetics and metabolism 2022; (137(1-2)):26-32 doi:10.1016/j.ymgme.2022.07.009.

    PMID: 35878504
  5. 5

    Determination of Health Concepts in β-Propeller Protein-Associated Neurodegeneration.

    Kotes E, Gavazzi F, Woidill S, et al.

    Journal of child neurology 2025; (40(1)):15-25 doi:10.1177/08830738241283932.

    PMID: 39376195
  6. 6

    Childhood Dystonia-Parkinsonism Following Infantile Spasms-Clinical Clue to Diagnosis in Early Beta-Propeller Protein-Associated Neurodegeneration.

    Hornemann F, Le Duc D, Roth C, et al.

    Neuropediatrics 2020; (51(1)):22-29 doi:10.1055/s-0039-1696688.

    PMID: 31505688
  7. 7

    Severe infantile onset developmental and epileptic encephalopathy caused by mutations in autophagy gene WDR45.

    Carvill GL, Liu A, Mandelstam S, et al.

    Epilepsia 2018; (59(1)):e5-e13 doi:10.1111/epi.13957.

    PMID: 29171013
  8. 8

    Phenotypic and Imaging Spectrum Associated With WDR45.

    Adang LA, Pizzino A, Malhotra A, et al.

    Pediatric neurology 2020; (109()):56-62 doi:10.1016/j.pediatrneurol.2020.03.005.

    PMID: 32387008
  9. 9

    Clinical features of a female with WDR45 mutation complicated by infantile spasms: a case report and literature review.

    Morikawa M, Takano K, Motobayashi M, et al.

    Brain & development 2017; (39(9)):804-807 doi:10.1016/j.braindev.2017.05.003.

    PMID: 28551038
  10. 10

    Clinical features and blood iron metabolism markers in children with beta-propeller protein associated neurodegeneration.

    Belohlavkova A, Sterbova K, Betzler C, et al.

    European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society 2020; (28()):81-88 doi:10.1016/j.ejpn.2020.07.010.

    PMID: 32811771
  11. 11

    A Comprehensive Overview of the Clinical, Electrophysiological, and Neuroimaging Features of BPAN: Insights From a New Case Series.

    Susgun S, Kizek O, Ugur Iseri SA, et al.

    Annals of clinical and translational neurology 2026; (13(3)):453-465 doi:10.1002/acn3.70220.

    PMID: 41097835
  12. 12

    Epileptic spasms: a previously unreported manifestation of WDR45 gene mutation.

    Xixis KI, Mikati MA

    Epileptic disorders : international epilepsy journal with videotape 2015; (17(4)):467-72 doi:10.1684/epd.2015.0784.

    PMID: 26609730
  13. 13

    Early-onset presentation of a new subtype of β-Propeller protein-associated neurodegeneration (BPAN) caused by a de novo WDR45 deletion in a 6 year-old female patient.

    Christoforou S, Christodoulou K, Anastasiadou V, Nicolaides P

    European journal of medical genetics 2020; (63(3)):103765 doi:10.1016/j.ejmg.2019.103765.

    PMID: 31536831
  14. 14

    The Clinical, Radiological and Genetic Spectrum of PLA2G6-Associated Neurodegeneration: An Experience From a Tertiary Center.

    Holla VV, Samim MM, Kumari R, et al.

    Tremor and other hyperkinetic movements (New York, N.Y.) 2024; (14()):41 doi:10.5334/tohm.897.

    PMID: 39184971
  15. 15

    Palliative care in 9 children with neurodegeneration with brain iron accumulation.

    Dangel T, Kmieć T, Januszaniec A, Ważny B

    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2020; (41(3)):653-660 doi:10.1007/s10072-019-04099-5.

    PMID: 31758347
  16. 16

    Precision Medicine in Neurodegeneration with Brain Iron Accumulation (NBIA) Disorders: An Update on Emerging Treatments.

    Schneider SA, Garg D, Iankova V, Klopstock T

    Movement disorders clinical practice 2026; doi:10.1002/mdc3.70736.

    PMID: 42429179
  17. 17

    A Patient with Beta-Propeller Protein-Associated Neurodegeneration: Treatment with Iron Chelation Therapy.

    Lim SY, Tan AH, Ahmad-Annuar A, et al.

    Journal of movement disorders 2018; (11(2)):89-92 doi:10.14802/jmd.17082.

    PMID: 29860786
  18. 18

    Patient Affected by Beta-Propeller Protein-Associated Neurodegeneration: A Therapeutic Attempt with Iron Chelation Therapy.

    Fonderico M, Laudisi M, Andreasi NG, et al.

    Frontiers in neurology 2017; (8()):385 doi:10.3389/fneur.2017.00385.

    PMID: 28878728
  19. 19

    WDR45 variants cause ferrous iron loss due to impaired ferritinophagy associated with nuclear receptor coactivator 4 and WD repeat domain phosphoinositide interacting protein 4 reduction.

    Tsukida K, Muramatsu SI, Osaka H, et al.

    Brain communications 2022; (4(6)):fcac304 doi:10.1093/braincomms/fcac304.

    PMID: 36751498

This BPAN treatment information is for education and does not replace medical advice. Work with your neurologist and multidisciplinary care team before changing medicines or starting therapies.

Get notified when new evidence is published on Beta-propeller protein-associated neurodegeneration.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.